Clinical Trial Update: Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial of Albinterferon alfa-2b in Chronic Hepatitis B was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Albinterferon alfa-2b (albinterferon alfa-2b)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Hepatitis B | Phase 1, Phase 2 | Status: TERMINATED